- Home
- IBCP vs BCAX Comparison
IBCP vs BCAX Comparison
Compare IBCP & BCAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBCP
- BCAX
- Stock Information
- Founded
- IBCP 1864
- BCAX 2018
- Country
- IBCP United States
- BCAX United States
- Employees
- IBCP N/A
- BCAX N/A
- Industry
- IBCP Major Banks
- BCAX
- Sector
- IBCP Finance
- BCAX
- Exchange
- IBCP Nasdaq
- BCAX NYSE
- Market Cap
- IBCP 630.0M
- BCAX 670.9M
- IPO Year
- IBCP N/A
- BCAX 2024
- Fundamental
- Price
- IBCP $30.12
- BCAX $12.16
- Analyst Decision
- IBCP Hold
- BCAX Buy
- Analyst Count
- IBCP 3
- BCAX 7
- Target Price
- IBCP $39.17
- BCAX $29.67
- AVG Volume (30 Days)
- IBCP 128.3K
- BCAX 516.6K
- Earning Date
- IBCP 04-24-2025
- BCAX 05-16-2025
- Dividend Yield
- IBCP 3.46%
- BCAX N/A
- EPS Growth
- IBCP 13.26
- BCAX N/A
- EPS
- IBCP 3.16
- BCAX N/A
- Revenue
- IBCP $218,142,000.00
- BCAX N/A
- Revenue This Year
- IBCP N/A
- BCAX N/A
- Revenue Next Year
- IBCP $6.51
- BCAX N/A
- P/E Ratio
- IBCP $9.53
- BCAX N/A
- Revenue Growth
- IBCP 8.64
- BCAX N/A
- 52 Week Low
- IBCP $22.53
- BCAX $8.91
- 52 Week High
- IBCP $40.32
- BCAX $28.09
- Technical
- Relative Strength Index (RSI)
- IBCP 48.39
- BCAX N/A
- Support Level
- IBCP $28.05
- BCAX N/A
- Resistance Level
- IBCP $30.84
- BCAX N/A
- Average True Range (ATR)
- IBCP 1.28
- BCAX 0.00
- MACD
- IBCP 0.18
- BCAX 0.00
- Stochastic Oscillator
- IBCP 74.07
- BCAX 0.00
About IBCP Independent Bank Corporation
Independent Bank Corp (Ionia MI) operates as a commercial bank. It offers a broad range of banking services to individuals and businesses, including checking and savings accounts, commercial lending, direct and indirect consumer financing, mortgage lending, and safe deposit box services. It also provides internet and mobile banking capabilities to its customers.
About BCAX BICARA THERAPEUTICS INC
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.